NASDAQ$ORIC
ORIC Pharmaceuticals Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
ORIC Pharmaceuticals reported financial results and operational updates for Q1 2023.
ORIC Pharmaceuticals reported cash and investments of $208.9 million, expected to fund the operating plan into the first half of 2025. The company is advancing its novel oncology pipeline, with initial Phase 1b data expected in the second half of 2023 for three ongoing clinical trials.
- Initial Phase 1b data for ORIC-533 in multiple myeloma is expected in the second half of 2023.
- Initial Phase 1b data for ORIC-114 in EGFR/HER2-mutated cancers is expected in the second half of 2023.
- Initial Phase 1b data for ORIC-944 in prostate cancer is expected in the second half of 2023.
- Preclinical data for ORIC-944 and PLK4 program were presented at the 2023 AACR Annual Meeting.
Headline financials
Revenue & EPS history
ORIC Pharmaceuticals · Revenue · Quarterly
$0
Forward guidance
ORIC Pharmaceuticals expects the cash and investments of $208.9 million as of March 31, 2023 will be sufficient to fund its operating plan into the first half of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+1.2%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+8.0%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+14.7%
Q2 2023
Best reaction
-29.8%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +14.7% | +14.9% | +5.7% | |
| Q3 2025 | +0.3% | -5.8% | -23.1% | |
| Q2 2025 | -1.0% | -7.9% | +8.9% | |
| Q1 2025 | +8.7% | +25.8% | +98.9% | |
| Q4 2024 | +0.8% | +2.1% | -43.5% | |
| Q3 2024 | -0.3% | -17.5% | -18.2% | |
| Q1 2024 | -1.0% | -7.4% | -5.6% | |
| Q4 2023 | -4.5% | +0.7% | -33.3% | |
| Q3 2023 | -3.2% | -11.9% | +26.4% | |
| Q2 2023 | +14.7% | +13.8% | +17.3% | |
| Q1 2023 | -0.4% | +0.1% | +11.4% | |
| Q4 2022 | +5.3% | +14.8% | +39.5% | |
| Q3 2022 | +2.8% | +17.9% | +35.4% | |
| Q2 2022 | +3.2% | -2.1% | -26.4% | |
| Q1 2022 | -3.4% | -4.4% | +52.0% | |
| Q4 2021 | -29.8% | -33.0% | -42.6% | |
| Q3 2021 | +7.1% | +8.4% | -7.1% | |
| Q2 2021 | +9.4% | +13.6% | +45.2% | |
| Q1 2021 | +2.1% | +6.1% | -17.0% | |
| Q4 2020 | -6.2% | -7.6% | -10.2% | |
| Q3 2020 | +3.8% | +4.4% | +55.6% | |
| Q2 2020 | +12.5% | +12.4% | +7.8% | |
| Q1 2020 | -8.7% | -11.3% | +7.3% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro